AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2018
Dec 16, 2018
33869_rns_2018-12-16_cbf961c5-637b-4b1e-baf3-bd8d0ec1bb24.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
17 December 2018
==> picture [451 x 24] intentionally omitted <==
ASX ANNOUNCEMENT
ASX Market Announcements Australian Securities Exchange Limited 20 Bridge Street SYDNEY NSW 2000
Admedus Limited (ASX:AHZ)
NOTICE OF DELAY OF ALLOTMENT IN SHARES
Admedus Limited ( Admedus ) advises that it now expects to allot the New Shares and New Options as part of the partially underwritten renounceable pro-rata entitlement offer announced to ASX on Wednesday, 28 November 2018 ( Entitlement Offer ) on Tuesday, 18 December 2018.
The revised date for the allotment of New Shares and New Options is the result of a delay in the receipt of funds from underwriters to the Entitlement Offer due to the time required to complete international money transfers.
Holding statements are now expected to be despatched on Thursday, 20 December 2018.
The anticipated date for commencement of normal trading of the new Shares on ASX is Wednesday, 19 December 2018.
ENDS
Admedus Limited
Registered Office:
T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299 E: [email protected] W: admedus.com
==> picture [72 x 72] intentionally omitted <==
Level 9, 301 Coronation Drive, Milton, Queensland 4064 Customer Service:
Brisbane • Minneapolis • Geneva • Singapore
ABN 35 088 221 078
==> picture [451 x 24] intentionally omitted <==
About Admedus Limited
Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Website: www.admedus.com
Facebook: www.facebook.com/Admedus Twitter: @Admedus
For more information, please contact:
Share Registry
Computershare Investor Services Pty Ltd Telephone: 1300 557 010 (within Aust) +61 3 9415 4000 (outside Aust) Facsimile: +61 3 9473 2500
Investor Relations
Kyahn Williamson WE Buchan [email protected] 03 9866 4722
==> picture [24 x 25] intentionally omitted <==